Targeted Therapy (Investigational)

44 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.

Connect With Us

+63 919 076 9100

Targeted Therapy (Investigational) (44)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Molecule	Drug Class / Mechanism	Oncology Type	Inquiry
Selumetinib Sulfate	DNA Damage Response Inhibitor	Solid Tumour
Molecule Selumetinib Sulfate Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Simtuzumab	Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)	Solid Tumour
Molecule Simtuzumab Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)
Telaglenastat	Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)	Solid Tumour
Molecule Telaglenastat Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)
Tozasertib	Polo-Like / Aurora Kinase Inhibitor	Both (Solid & Hematologic)
Molecule Tozasertib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
Tulmimetostat	Dual EZH2/EZH1 Inhibitor	Both (Solid & Hematologic)
Molecule Tulmimetostat Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Dual EZH2/EZH1 Inhibitor
Tunlametinib	DNA Damage Response Inhibitor	Solid Tumour
Molecule Tunlametinib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Volasertib	Polo-Like / Aurora Kinase Inhibitor	Both (Solid & Hematologic)
Molecule Volasertib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
Zoldonrasib	RAS(ON) G12D-Selective Tri-Complex Inhibitor	Solid Tumour
Molecule Zoldonrasib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism RAS(ON) G12D-Selective Tri-Complex Inhibitor

Selumetinib Sulfate Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Simtuzumab Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)
Telaglenastat Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)
Tozasertib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
Tulmimetostat Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Dual EZH2/EZH1 Inhibitor
Tunlametinib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism DNA Damage Response Inhibitor
Volasertib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
Zoldonrasib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism RAS(ON) G12D-Selective Tri-Complex Inhibitor

‹ 1 2 3 4 ›